QQQ   422.29 (-0.26%)
AAPL   165.45 (-0.95%)
MSFT   402.79 (-0.37%)
META   494.61 (-1.43%)
GOOGL   154.86 (-0.74%)
AMZN   177.91 (-0.73%)
TSLA   148.66 (-0.85%)
NVDA   839.38 (-0.87%)
AMD   153.36 (-1.11%)
NIO   3.86 (-3.50%)
BABA   68.71 (-0.25%)
T   16.39 (+0.37%)
F   12.18 (+1.00%)
MU   109.70 (-1.99%)
GE   152.93 (+-0.01%)
CGC   8.22 (+4.98%)
DIS   112.24 (-0.17%)
AMC   3.07 (+5.14%)
PFE   25.45 (+0.24%)
PYPL   62.09 (-0.02%)
XOM   120.08 (+1.32%)
QQQ   422.29 (-0.26%)
AAPL   165.45 (-0.95%)
MSFT   402.79 (-0.37%)
META   494.61 (-1.43%)
GOOGL   154.86 (-0.74%)
AMZN   177.91 (-0.73%)
TSLA   148.66 (-0.85%)
NVDA   839.38 (-0.87%)
AMD   153.36 (-1.11%)
NIO   3.86 (-3.50%)
BABA   68.71 (-0.25%)
T   16.39 (+0.37%)
F   12.18 (+1.00%)
MU   109.70 (-1.99%)
GE   152.93 (+-0.01%)
CGC   8.22 (+4.98%)
DIS   112.24 (-0.17%)
AMC   3.07 (+5.14%)
PFE   25.45 (+0.24%)
PYPL   62.09 (-0.02%)
XOM   120.08 (+1.32%)
QQQ   422.29 (-0.26%)
AAPL   165.45 (-0.95%)
MSFT   402.79 (-0.37%)
META   494.61 (-1.43%)
GOOGL   154.86 (-0.74%)
AMZN   177.91 (-0.73%)
TSLA   148.66 (-0.85%)
NVDA   839.38 (-0.87%)
AMD   153.36 (-1.11%)
NIO   3.86 (-3.50%)
BABA   68.71 (-0.25%)
T   16.39 (+0.37%)
F   12.18 (+1.00%)
MU   109.70 (-1.99%)
GE   152.93 (+-0.01%)
CGC   8.22 (+4.98%)
DIS   112.24 (-0.17%)
AMC   3.07 (+5.14%)
PFE   25.45 (+0.24%)
PYPL   62.09 (-0.02%)
XOM   120.08 (+1.32%)
QQQ   422.29 (-0.26%)
AAPL   165.45 (-0.95%)
MSFT   402.79 (-0.37%)
META   494.61 (-1.43%)
GOOGL   154.86 (-0.74%)
AMZN   177.91 (-0.73%)
TSLA   148.66 (-0.85%)
NVDA   839.38 (-0.87%)
AMD   153.36 (-1.11%)
NIO   3.86 (-3.50%)
BABA   68.71 (-0.25%)
T   16.39 (+0.37%)
F   12.18 (+1.00%)
MU   109.70 (-1.99%)
GE   152.93 (+-0.01%)
CGC   8.22 (+4.98%)
DIS   112.24 (-0.17%)
AMC   3.07 (+5.14%)
PFE   25.45 (+0.24%)
PYPL   62.09 (-0.02%)
XOM   120.08 (+1.32%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$3.53
+1.1%
$3.75
$2.31
$6.75
$43.56M1.6128,713 shs7,831 shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$2.05
+2.0%
$2.80
$1.62
$4.27
$83.68M0.2313,979 shs106 shs
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$33.97
$33.70
$20.35
$34.38
$1.50B0.23973,737 shsN/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
+1.15%+9.63%-0.56%-20.76%-37.48%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-4.74%-16.25%-28.47%-31.28%-5.19%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
0.9943 of 5 stars
3.34.00.00.00.00.00.6
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
2.50
Moderate Buy$4.4526.06% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
2.00
HoldN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/A

Current Analyst Ratings

Latest TKNO, VIVO, and AWH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.30
4/1/2024
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.30
3/12/2024
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$9.15M4.76N/AN/A($0.23) per share-15.35
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$36.68M2.28N/AN/A$2.21 per share0.93
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$333.02M4.49$1.78 per share19.13$8.41 per share4.04

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
-$16.69M-$12.01N/AN/AN/A-176.74%-1,099.32%-189.56%5/9/2024 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$36.78M-$1.16N/AN/AN/A-100.26%-38.12%-25.95%5/8/2024 (Estimated)
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$42.46M$0.9735.02N/A12.70%16.74%13.09%N/A

Latest TKNO, VIVO, and AWH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/11/2024Q4 2023
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.23-$0.22+$0.01-$0.18$8.20 million$7.87 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
N/A
1.03
0.99
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.15
5.14
3.84
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.07
3.63
2.46

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
12.19%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
89.72%

Insider Ownership

CompanyInsider Ownership
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
4.30%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
15.20%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
2.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
6412.34 million11.81 millionNo Data
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
28540.82 million34.62 millionNot Optionable
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
70244.01 million43.00 millionOptionable

TKNO, VIVO, and AWH Headlines

SourceHeadline
Vivo X100s Pro with new Dimensity 9300 Plus chip could be launching soonVivo X100s Pro with new Dimensity 9300 Plus chip could be launching soon
gizmochina.com - March 24 at 6:33 AM
Vivo V30 Pro review: Flagship-grade imaging system in a slender form factorVivo V30 Pro review: Flagship-grade imaging system in a slender form factor
business-standard.com - March 13 at 2:11 AM
Vivo X Fold 3 Series tipped to outshine iPhone 15 Pro in slimness and weight: ReportVivo X Fold 3 Series tipped to outshine iPhone 15 Pro in slimness and weight: Report
livemint.com - March 11 at 9:30 AM
Meridian Meadows Transitional CareMeridian Meadows Transitional Care
health.usnews.com - February 8 at 6:28 AM
Kendall Ford of MeridianKendall Ford of Meridian
cars.com - January 20 at 12:52 PM
Meridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to SustainabilityMeridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to Sustainability
benzinga.com - November 28 at 3:05 PM
Vivo V29 & V29 Pro coming to India later this month; what we know so farVivo V29 & V29 Pro coming to India later this month; what we know so far
gizmochina.com - September 15 at 5:11 PM
Vivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, MoreVivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, More
news.abplive.com - September 1 at 8:48 PM
Vivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, MoreVivo V29e Challengers: iQoo Z7 Pro, Nothing Phone 1, More
news.abplive.com - September 1 at 8:48 PM
Meridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA FlexMeridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA Flex
finance.yahoo.com - July 25 at 7:45 PM
Snapdragon 4 Gen 2 Uses 4nm Platform, Will Power Mid-Range Phones Later This YearSnapdragon 4 Gen 2 Uses 4nm Platform, Will Power Mid-Range Phones Later This Year
droid-life.com - June 26 at 2:14 PM
Mammalian Rho GTPases: new insights into their functions from in vivo studiesMammalian Rho GTPases: new insights into their functions from in vivo studies
nature.com - June 24 at 2:57 PM
Epidemiology, Diagnosis and Treatment ofEpidemiology, Diagnosis and Treatment of
medscape.com - June 11 at 7:57 AM
Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Future Market InsightsOncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Future Market Insights
fmiblog.com - June 7 at 10:07 AM
Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Get Insights FMIOncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033 | Get Insights FMI
fmiblog.com - June 2 at 1:18 PM
Rapid Testing Kits Market Size Opportunities, Top Countries Data, Future Trends and Share Forecast 2028Rapid Testing Kits Market Size Opportunities, Top Countries Data, Future Trends and Share Forecast 2028
marketwatch.com - May 17 at 10:20 AM
Rapid Testing Kits Market Size with Growth Opportunities, Top Countries Data, Future Trends and Share with Revenue Forecast 2028Rapid Testing Kits Market Size with Growth Opportunities, Top Countries Data, Future Trends and Share with Revenue Forecast 2028
marketwatch.com - April 27 at 2:10 AM
Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)
thestreet.com - April 19 at 11:37 PM
Meridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin AssayMeridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay
markets.businessinsider.com - April 19 at 6:36 PM
Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033Oncology-Based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033
fmiblog.com - April 7 at 10:46 AM
Former executives at Meridian Bioscience subsidiary facing federal chargesFormer executives at Meridian Bioscience subsidiary facing federal charges
bizjournals.com - April 6 at 6:34 PM
Meridian Bioscience Comments on DOJ Announcement Regarding Former Executives of Magellan DiagnosticsMeridian Bioscience Comments on DOJ Announcement Regarding Former Executives of Magellan Diagnostics
markets.businessinsider.com - April 5 at 8:46 PM
Diagnostics execs charged with concealing lead test flawDiagnostics execs charged with concealing lead test flaw
medtechdive.com - April 5 at 8:46 PM
Meridian Bioscience Stock Hits New 52-Week Low (VIVO)Meridian Bioscience Stock Hits New 52-Week Low (VIVO)
thestreet.com - March 30 at 11:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aspira Women

Aspira Women's Health

NASDAQ:AWH
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
Alpha Teknova logo

Alpha Teknova

NASDAQ:TKNO
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It also provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Meridian Bioscience logo

Meridian Bioscience

NASDAQ:VIVO
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.